DEF: Daxor Corporation Sets Annual Meeting for June 23, 2026

Daxor Corporation has issued its proxy statement for the Annual Meeting of Stockholders scheduled for June 23, 2026, detailing proposals for director elections and auditor ratification.

Summary

• Daxor Corporation is holding its Annual Meeting of Stockholders on June 23, 2026, at the Nasdaq Stock Exchange in New York.
• The primary purposes of the meeting are to elect a board of six directors and to ratify the appointment of Bush & Associates, CPA as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The Board of Directors recommends a vote FOR all director nominees and FOR the ratification of the accounting firm.
• Stockholders of record as of May 20, 2026, are entitled to vote.
• The company is also providing access to its proxy materials and most recent Annual Report on Form N-CSR online and upon request.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily containing routine procedural information for an annual shareholder meeting. While it addresses governance structure, it does not present new financial performance data or strategic shifts that would significantly alter the investment outlook.

Positives

• The company is holding its annual meeting as scheduled, indicating ongoing operational activity.
• The Board of Directors is recommending a slate of nominees and the continued engagement of the current accounting firm, suggesting stability in governance and financial oversight.
• The audit committee has reviewed and discussed the financial statements with management and the independent auditor, receiving an unqualified audit opinion.
• The company has a compliance program and a code of ethics program in place, meeting regulatory requirements.

Negatives

• The company notes that should the interests of the Feldschuh Estate, its largest shareholder (43.7%), differ from other stockholders, those other stockholders may not have the same protections as those in companies subject to all Nasdaq corporate governance rules, as Daxor does not currently have a standing compensation or nominating committee charter.
• Two of the director nominees, Michael Feldschuh and Jonathan Feldschuh, are classified as interested persons due to their employment with the company, which could raise governance concerns for some investors.

Risks

• The company acknowledges that it is not practicable or possible to identify all risks or develop controls to eliminate all risk exposures.
• Potential divergence of interests between the largest shareholder (Feldschuh Estate) and other stockholders due to the absence of formal compensation and nominating committees.
• The company is not primarily engaged in the business of investing, reinvesting, owning, holding or trading in securities, and its CEO manages any excess capital, which could present investment risks if not managed prudently.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines the agenda for the upcoming annual meeting, including the election of directors and ratification of the auditor, and provides information on stockholder proposals for the 2027 annual meeting.

Management Comments

• The Board of Directors recommends a vote FOR ALL NOMINEES in Proposal 1 (Election of Directors) and FOR ratification of the appointment of Bush & Associates, CPA in Proposal 2.
• Management will report on the company's performance during 2025 and respond to stockholder questions at the Annual Meeting.
• The company has overseen the development and administration of a compliance program and a code of ethics program that meet regulatory requirements.

Industry Context

StockSavvy.ai notes that this filing is a standard proxy statement for an annual meeting, typical for publicly traded companies. The focus on director elections and auditor ratification is routine. The mention of potential governance differences compared to Nasdaq listing rules for companies with significant controlling shareholders is a point of interest for governance-focused investors.

Comparison to Industry Standards

• The company's board structure, with four independent directors out of six, aligns with general corporate governance best practices, although the absence of formal compensation and nominating committee charters is less common for companies aiming for full Nasdaq compliance.
• The fees paid to the independent auditor ($75,000 for audit in FY2025) are within a reasonable range for a company of this size, though specific industry benchmarks would require more detailed financial data.
• The compensation for officers like John Jefferies, MD ($299,476) appears to be within typical ranges for Chief Medical Officers in biotech or healthcare-related firms, depending on the company's stage and market.

Corporate Governance

Related Party Transactions

• Michael Feldschuh and Jonathan Feldschuh are brothers and are classified as interested persons due to their employment with the Company. Their compensation and stock ownership are disclosed.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification. Potential governance concerns may arise from the largest shareholder's influence and the current lack of formal committee charters.
• Employees: The compensation of key officers (Michael Feldschuh, Jonathan Feldschuh, Robert J. Michel, John Jefferies, MD) is disclosed.
• Management: The filing outlines their roles and responsibilities in the context of the annual meeting and corporate governance.

Next Steps

• Stockholders are urged to vote their proxies in advance of the Annual Meeting.
• The company will hold its Annual Meeting of Stockholders on June 23, 2026.
• Stockholder proposals for the 2027 Annual Meeting must be received by February 6, 2027.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial results, strategic updates, or significant operational news that would warrant a change in investment recommendation. It confirms standard corporate procedures are being followed, but also highlights potential governance considerations related to controlling shareholders and the ongoing development of formal committee structures.

Keywords

Daxor Corporation, Proxy Statement, Annual Meeting, DEF 14A, SEC Filing, Board of Directors, Independent Auditor, Stockholder Meeting, Corporate Governance, Election of Directors, Audit Committee